Shire Adds Two Pipeline Products With TKT Acquisition
Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate
You may also be interested in...
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
By adding Pervasis’ endothelial cell technology to the expertise it added with last year’s buyout of Advanced BioHealing, Shire is hoping to build its Regenerative Medicine unit into another powerhouse division, like its Human Genetic Therapies unit.
“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 4